Adam ElsesserChairman and Chief Executive Officer
Adam co-founded Penumbra and has served as Chief Executive Officer and a member of our board of directors since our inception in 2004, as Chairman of our board of directors since January 2015, and as President from January 2015 until August 2019. Prior to Penumbra, Adam led SMART Therapeutics, Inc., a medical device company focused on devices for neuro-intervention, as its Chief Executive Officer from 2000 to 2002 and, after its acquisition by Boston Scientific Corporation, President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Before his work in the medical device industry, Adam was a partner in the law firm of Shartsis Friese LLP. He received a BA from Stanford University and a JD from Hastings College of the Law.
Arani Bose, MD
Arani Bose, MDChief Innovator and Director
Arani co-founded Penumbra in 2004 and has served as a member of our board of directors since our inception. He was Chairman of our board of directors and Chief Medical Officer from 2005 until 2015 and currently serves as Chief Innovator. Prior to founding Penumbra, Arani was an Assistant Professor of Radiology and Neurology at New York University (NYU) School of Medicine from 1997 to 2004, where he also had a clinical practice. While at NYU, Arani co-founded SMART Therapeutics. He received a BA from Stanford University and an MD from the University of Colorado School of Medicine with residency and fellowships at Yale University School of Medicine and NYU Medical Center.
Sri joined Penumbra in 2015, serving as Chief Financial Officer and Head of Strategy until his promotion in August 2019. Prior to joining Penumbra, he worked in investment banking for J.P. Morgan Securities LLC (J.P. Morgan) from 1999 to 2015, where he held a variety of positions with successively greater responsibility, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Prior to entering J.P. Morgan’s equity capital markets group in 2006, Sri served in various practice groups at J.P. Morgan, including Equity Derivatives from 2003 to 2006 and Technology, Media, Telecom Investment Banking Coverage from 1999 to 2003. Sri currently serves on the board of 10x Genomics, Inc. (NASDAQ: TXG), a publicly traded Lifesciences technology company. He received a BS from Massachusetts Institute of Technology in 1999.
Lynn RothmanExecutive Vice President and Chief Business Officer
Lynn joined Penumbra in 2007. She has served as Executive Vice President and Chief Business Officer since January 2015; as Chief Financial Officer from March 2009 to January 2015; as Vice President, Administration from January 2009 to March 2009, and as Human Resources Manager from 2007 to January 2009. She joined Penumbra with over 20 years of experience in finance and marketing of medical and emerging growth companies. Lynn served as Director of Corporate Marketing at Confer Software, Inc., a disease management company, from 1997 to 2000. Prior to that time, she worked at Robertson Stephens & Company, a financial services firm, where she worked in both health care research and venture capital focused on potential medical device, service and software investment opportunities. Lynn received an MBA from The Wharton School, University of Pennsylvania and a BA from Stanford University.
Maggie YuenChief Financial Officer
Maggie joined Penumbra in 2019, serving as Chief Financial Officer. Prior to Penumbra, Maggie spent more than 20 years of progressive leadership experience driving scalable finance organizations, processes and infrastructure in the Manufacturing, Medical Devices, and Life Science industries. She most recently served as Vice President of Finance of the Genetic Science Division within Thermo Fisher Scientific, Inc. (NYSE: TMO), a business focused on instrument platforms, cloud-based software, content and services. In her role, she directed finance operations, strategic planning and business development activities, among a number of other executive functions. Prior to Thermo Fisher, Maggie held leadership positions with increasing responsibility at Mirion Technologies, and senior finance roles at Boston Scientific (NYSE: BSX), Glu Mobile (NASDAQ: GLUU), and Johnson & Johnson (NYSE: JNJ). She received an MAcc and MBA from the Weatherhead School of Management and a BS from Case Western Reserve University.
Lambert ShiuChief Accounting Officer
Lambert joined Penumbra in 2015, serving as Director of Finance, then as Vice President, Finance and Accounting until his promotion to Chief Accounting Officer in 2019. Prior to joining Penumbra, he worked for PricewaterhouseCoopers, LLP (“PwC”), an accounting firm, for 13 years. He worked on a variety of teams during his tenure at PwC, each role increasing in levels of responsibility and management and spent two years in their National Office. Lambert is a Certified Public Accountant in California and received a BA from the University of California, Davis in 2001.
David BarryChief Technology Officer
Dave joined Penumbra in 2004 leading the development effort for the Penumbra System. Currently, as CTO, he is responsible for evaluating all new technologies. Prior to his role as CTO, Dave was the Vice President of Research and Development overseeing all product development efforts at Penumbra. Before joining Penumbra, he held roles of increasing responsibility at SMART Therapeutics, Boston Scientific, WL Gore & Associates, and Cordis, a Johnson & Johnson Company. Dave holds a Bachelor’s of Science in Chemical Engineering from Northeastern University and is a veteran of the United States Air Force.
Johanna RobertsExecutive Vice President, General Counsel and Secretary
Johanna joined the Penumbra legal team in 2014, serving as Vice President and Deputy General Counsel from July 2015 until her promotion to Executive Vice President and General Counsel in September 2018. Johanna joined Penumbra with more than fifteen years’ experience working for several law firms, including Morrison & Foerster LLP in San Francisco. Johanna received her law degree from Harvard Law School and her undergraduate degree from Dartmouth College.
Kathleen KiddVice President of Quality and Compliance
Kathleen joined Penumbra in 2007 and has served as Vice President of Quality and Compliance since 2009. Before joining Penumbra, Kathleen had over 20 years of experience in the bio-pharmaceutical and medical device industries. Kathleen started her career in the life science field working for 8 years at Genentech in the quality department followed by over 10 years at Chiron Corporation. Following her tenure at Chiron, she spent 8 years serving as a Senior Auditor with KEMA, a Dutch notified body, performing quality systems assessments throughout the world. During her time with KEMA, Kathleen participated in the first class of FDA AP auditors and was accredited in various countries to perform regulatory assessments and audits. She earned her bachelor’s degree from Mills College in Biology, followed by graduate work in the Veterinary Sciences.
Gita BarryVice President, Global Marketing
Gita joined Penumbra as Vice President, Global Marketing, Neuro in January 2016. Prior to joining Penumbra, Gita worked at Stryker Corporation for twelve years where she held a variety of positions with successively greater responsibility in both Stryker’s Orthopedics Group and Neurovascular division in product management, strategy, business development/integration and information technology. Prior to Stryker, Gita held various product development roles with other cardiovascular medical device companies including WL Gore and Associates and Cordis, a Johnson & Johnson company, in the areas of coronary and peripheral vascular products. Gita received a BS in Biomedical Engineering from the University of Miami (FL) and an Executive MBA from Santa Clara University.
Ben TompkinsVice President Research and Development
Ben joined Penumbra in 2004 as the company’s third employee. He was a member of the engineering development teams for the Penumbra System, Neuron, and Penumbra Coil 400 product lines before taking on the role of Director, Research & Development in 2010. Ben has served in his current role as Vice President of Research & Development since 2013, where he spends the bulk of his time working closely with Penumbra’s highly collaborative and dynamic R&D team. He received a BS in Mechanical Engineering and MS in Mechanical and Aeronautical Engineering from the University of California, Davis.
Ben SorciVice President of Manufacturing Engineering
Ben was an early team-member of Penumbra, starting as an Engineer in 2005. He has worked on the design, development and manufacturing of many Penumbra products including the Penumbra System, Neuron, Penumbra Coil 400, Indigo System, Ruby Coil, Apollo System and Penumbra SMART COIL. He has been serving in his current role as Vice President of Manufacturing Engineering since 2013. Prior to starting at Penumbra, Ben held engineering roles at Boston Scientific in the neurovascular division and at SMART Therapeutics, a medical device company focused on devices for neuro-intervention. He received a BS in Mechanical Engineering from California Polytechnic State University, San Luis Obispo.
Ryan PowersVice President of Operations C.P.I.M.
Ryan joined Penumbra in 2007. Ryan’s background is in Planning and Execution where he has spent over 20 years in the medical device industry. Before joining Penumbra, he held positions at Boston Scientific, SMART Therapeutics, WL Gore, and Raychem. Ryan has 8 children, and 3 grandchildren, loves golfing and riding motorcycles.
Michaella CorsoVice President of Clinical Affairs
Michaella Corso joined Penumbra as Director of Clinical Affairs in 2016. Prior to Penumbra, Michaella worked at Intersect ENT from 2014 to 2016, where she led their pivotal drug/device combination product trial RESOLVE II. Prior to Intersect ENT, Michaella worked at Edwards Lifesciences from 2007 to 2014, where she held a variety of clinical positions focusing on Transcatheter Aortic Valve Replacement (TAVR) programs, resulting in the first FDA approval of an aortic heart valve placed without open heart surgery. Before her work in Clinical Research, Michaella served as a Health Educator in Tanzania focusing on HIV prevention. Michaella received a BS from University of California, Los Angeles.
Sharon HughesVice President of Human Resources
Sharon joined Penumbra as VP of HR in 2016. Prior to joining Penumbra, she served as VP, HR for Complete Genomics, a BGI company, focused on the design and build of genomic sequencing tools from 2013 to 2016. Sharon served from 2009 to 2013 as Head of HR for Janssen Alzheimer Immunotherapy, a company jointly established by Johnson & Johnson and Elan Pharmaceuticals to develop new treatments in Alzheimer’s disease. From 2000 to 2009, she worked in the medical device field and held various HR roles, including HR Director of LifeScan, a Johnson and Johnson company. Prior to 2000, Sharon held HR roles in the semiconductor and software consulting industries. She received a BS from California Polytechnic State University, San Luis Obispo (Cal Poly), Postgraduate Diploma in HRM from Manchester Metropolitan University in England, and an MBA from San Jose State University.
Pankaj TiwariVice President of Information Technology
Pankaj joined Penumbra in 2016 and currently serves as Vice President of Information Technology. He joined Penumbra with over 20 years of experience in the hi-tech, semiconductor and solar industries. Previously, Pankaj worked for Atmel Corporation as Sr. Director for Global Business Application from 2013 to 2016 and VP of IT for Nanosolar from 2011 to 2012. Prior to joining Nanosolar, he worked for Marvell Semiconductor, a leading fabless semiconductor company from 2002 to 2011 where he most recently served as Director, Business Applications. Pankaj earned his bachelor’s degree in Electrical Engineering at the Indian Institute of Technology, Varanasi, India, and an MBA in Information Systems and Marketing from California State University, East Bay.